Buy Rating Affirmed for Context Therapeutics Amid Promising CTIM-76 Developments and Competitive Edge
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected
US stocks look set to open higher in Thursday's trading session following the Federal Reserve's decision to leave rates unchanged Wednesday, and after jobless claims came in lower than expected earlie
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAllarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSol
Context Therapeutics Secures Funding, Advances Clinical Trials
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics
Context Therapeutics Announces $100 Million Private Placement
Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) --
Buy Rating on Context Therapeutics's CTIM-76 Bolstered by Market Validation and Competitive Edge
Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers
Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers
Context Therapeutics Advances Cancer Trial With FDA Submission
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a bio
Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics with a Buy and lowers the price target from $5 to $4.
Preston Fay Brings Data Analytics Leadership to The Context Network
WEST DES MOINES, Iowa, March 21, 2024 /PRNewswire/ -- Agribusiness consulting firm The Context Network (Context) is growing its data analytics practice, with Preston Fay joining the leadership team a
Context Therapeutics Reports FY Results
Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M
Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M
Press Release: Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Context Therapeutics Reports Full Year 2023 Operating and Financial Results CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Compan
Context Therapeutics Unveils Updated Corporate Strategy Presentation
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAclarion (NASDAQ:ACON) stock rose 21.6% to $3.82 during Friday's after-market session. The company's market cap stands at $3.2 million. Outset Medical (NASDAQ:OM) shares rose 10.61% to $4.95. T
No Data